Bio-Rad and 10X Genomics end patent fight with new licensing deal

Bio-Rad Laboratories has settled its long-running dispute with 10X Genomics over patents covering genetic analysis tech and both companies have negotiated an agreement to cross-license their products.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Amgen hit with lawsuit over its proposed Opdivo biosimilar

16 September 2026 BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.

Biotech

Australian biotech sues Grail over multi-cancer blood test

15 September 2026 Grail is facing a patent infringement lawsuit over its Galleri cancer detection test, as Clinical Genomics seeks to enforce its intellectual property while no longer being commercially operational.

Biotech

10x Genomics wins latest round in Parse patent dispute

3 September 2026 Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology.

More features

Leading European patent litigator to join Carpmaels & Ransford

CIPA Congress: Sustainability is essential for the profession and the planet

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

Inside the deal boom: LSIPR’s five-part M&A series—all in one place

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Australian biotech sues Grail over multi-cancer blood test

K&L Gates hires six-strong team of IP and corporate lawyers from Pillsbury

Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients

Bio-Rad and 10X Genomics end patent fight with new licensing deal

More on this story

Editor's picks

Editor's picks

More features